Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. (2017)
Attributed to:
Bone marrow stem cell therapy in multiple sclerosis: potential mechanisms of repair and protection
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s1474-4422(17)30007-8
PubMed Identifier: 28209331
Publication URI: http://europepmc.org/abstract/MED/28209331
Type: Journal Article/Review
Volume: 16
Parent Publication: The Lancet. Neurology
Issue: 4
ISSN: 1474-4422